Aspruzyo Sprinkle is a drug owned by Sun Pharma Industries Ltd. It is protected by 3 US drug patents filed from 2022 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 24, 2038. Details of Aspruzyo Sprinkle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11510878 | Extended release multiparticulates of ranolazine |
Jan, 2038
(12 years from now) | Active |
| US12161761 | Extended release multiparticulates of ranolazine |
Jan, 2038
(12 years from now) | Active |
| US10898444 | Extended release multiparticulates of ranolazine |
Jan, 2038
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aspruzyo Sprinkle's patents.
Latest Legal Activities on Aspruzyo Sprinkle's Patents
Given below is the list of recent legal activities going on the following patents of Aspruzyo Sprinkle.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 29 Nov, 2022 | US11510878 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Nov, 2022 | US11510878 |
| Email Notification Critical | 10 Nov, 2022 | US11510878 |
| Issue Notification Mailed Critical | 09 Nov, 2022 | US11510878 |
| Application Is Considered Ready for Issue Critical | 28 Oct, 2022 | US11510878 |
| Dispatch to FDC | 28 Oct, 2022 | US11510878 |
| Issue Fee Payment Verified Critical | 25 Oct, 2022 | US11510878 |
| Issue Fee Payment Received Critical | 25 Oct, 2022 | US11510878 |
| Mail Notice of Allowance Critical | 07 Oct, 2022 | US11510878 |
| Electronic Review Critical | 07 Oct, 2022 | US11510878 |
US patents provide insights into the exclusivity only within the United States, but Aspruzyo Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Aspruzyo Sprinkle's family patents as well as insights into ongoing legal events on those patents.
Aspruzyo Sprinkle's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Aspruzyo Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 24, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Aspruzyo Sprinkle Generic API suppliers:
Ranolazine is the generic name for the brand Aspruzyo Sprinkle. 26 different companies have already filed for the generic of Aspruzyo Sprinkle, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Aspruzyo Sprinkle's generic
Alternative Brands for Aspruzyo Sprinkle
There are several other brand drugs using the same active ingredient (Ranolazine) as Aspruzyo Sprinkle. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Menarini Intl |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ranolazine, Aspruzyo Sprinkle's active ingredient. Check the complete list of approved generic manufacturers for Aspruzyo Sprinkle
About Aspruzyo Sprinkle
Aspruzyo Sprinkle is a drug owned by Sun Pharma Industries Ltd. Aspruzyo Sprinkle uses Ranolazine as an active ingredient. Aspruzyo Sprinkle was launched by Spil in 2022.
Approval Date:
Aspruzyo Sprinkle was approved by FDA for market use on 28 February, 2022.
Active Ingredient:
Aspruzyo Sprinkle uses Ranolazine as the active ingredient. Check out other Drugs and Companies using Ranolazine ingredient
Dosage:
Aspruzyo Sprinkle is available in granules, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1GM | GRANULES, EXTENDED RELEASE | Discontinued | ORAL |
| 500MG | GRANULES, EXTENDED RELEASE | Discontinued | ORAL |